Oramed CFO receives 209,291 restricted shares

After 40% vests on the grant date, the remaining 60% vests in eight substantially equal quarterly installments over 24 months, subject to continued service.

Rhea-AI Filing Summary

ORAMED PHARMACEUTICALS INC. Chief Financial Officer Gabay Avraham acquired a restricted stock award of 209,291 shares on September 24, 2026, under the Amended and Restated 2019 Stock Incentive Plan. Forty percent vests on the grant date; the remaining 60% vests in eight substantially equal quarterly installments over the 24-month period following the grant, subject to continued service. Unvested shares are subject to forfeiture under the award agreement and Plan. His direct holdings following the award were 881,076 shares.

Insider Trade Summary

Grant/Award: 209,291 shares

Grant/Award 1 txn

Insider Gabay Avraham

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	209,291	--	--

Holdings After Transaction: Common Stock — 881,076 shares (Direct)

Footnotes (1)

1. F1. On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.

Key Figures

Restricted stock award: 209,291 shares Vesting on grant date: 40% Remaining award vesting: 60% +3 more

6 metrics

Restricted stock award 209,291 shares Granted September 24, 2026

Vesting on grant date 40% Restricted stock award

Remaining award vesting 60% Vests over the 24-month period following the grant

Quarterly installments 8 installments Substantially equal installments

Vesting period 24 months Following the grant date

Direct shares following award 881,076 shares Chief Financial Officer Gabay Avraham

Key Terms

restricted stock award, Amended and Restated 2019 Stock Incentive Plan, forfeiture

3 terms

restricted stock award financial

"restricted stock award of an aggregate of 209,291 shares"

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

Amended and Restated 2019 Stock Incentive Plan financial

"pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan"

forfeiture financial

"Unvested shares are subject to forfeiture"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did ORMP's CFO receive?

Chief Financial Officer Gabay Avraham received a restricted stock award of 209,291 shares on September 24, 2026. His direct holdings following the award were 881,076 shares. No Rule 10b5-1 plan is reported.

How does ORMP's CFO's restricted stock award vest?

Forty percent vests on the grant date, and the remaining 60% vests in eight substantially equal quarterly installments over the 24-month period following the grant, subject to continued service. Unvested shares are subject to forfeiture under the award agreement and Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/25/2026 - 04:43 PM Accepted by SEC EDGAR 09/25/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gabay Avraham

(Last) (First) (Middle)

1185 AVENUE OF THE AMERICAS

THIRD FLOOR

(Street)

NEW YORK 10036

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2026		A		209,291	A	(1)	881,076	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.

	/s/ Avraham Gabay	09/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)